HIGHLIGHTS
Intracardiac serum galectin (Gal)-3 levels are shown to be greater in patients with persistent than paroxysmal atrial fibrillation (AF), and the Gal-3 level was an independent predictor of AF recurrences after a single ablation procedure.
In a sheep model, the Gal-3 inhibitor GM-CT-01 (GMCT) reduced atrial fibroblast proliferation in vitro.
GMCT mitigated atrial dilation, myocyte hypertrophy, fibrosis, and the expected increase in DF during transition to persistent AF.
GMCT-treated sheep hearts had longer action potential durations, and fewer rotors and wavebreaks during AF than control.
GMCT increased the number of spontaneous AF terminations and reduced overall AF burden.
SUMMARY
Atrial fibrillation (AF) usually starts as paroxysmal but can evolve relentlessly to the persistent and permanent forms. However, the mechanisms governing such a transition are unknown. The authors show that intracardiac serum levels of galectin (Gal)-3 are greater in patients with persistent than paroxysmal AF and that Gal-3 independently predicts atrial tachyarrhythmia recurrences after a single ablation procedure. Using a sheep model of persistent AF the authors further demonstrate that upstream therapy targeting Gal-3 diminishes both electrical remodeling and fibrosis by impairing transforming growth factor beta-mediated signaling and reducing myofibroblast activation. Accordingly, Gal-3 inhibition therapy increases the proba- is highly expressed in fibrotic tissues (2-4); it associates with cardiac fibrosis during heart failure (5) and increases risk for heart failure and mortality (6) . Gal-3 contains a carbohydrate-binding domain linked by an amino-terminal nonlectin region that favors formation of Gal-3 pentamers (7). Gal-3 pentamers bind to transforming growth factor (TGF)-b receptors causing cell surface retention and internalization of the receptors, which is important for mediating duration and directionality of signaling through Smad and Akt proteins (8, 9) .
Recent studies demonstrated that serum Gal-3 is elevated in AF patients with preserved left ventricular function (10) . Contrastingly, others suggested that elevation of Gal-3 was driven by cardiometabolic comorbidities and not heart rhythm (11) . In the present study, we endeavored to determine whether Gal-3 mediates structural and electrical remodeling during AF progression. We conducted a blinded saline-controlled study in atrially tachypaced sheep with persistent AF (12) to investigate the effects of GM-CT-01 (GMCT), a galactomannan that inhibits Dr. Takemoto has been supported by the JHRS fellowship program from Medtronic Japan as well as the Uehara Memorial Foundation, and by a postdoctoral fellowship from the American Heart Association (14POST18220000 Investigators were blinded to treatment until the end of follow-up.
RESULTS
Fifty-five patients (Supplemental Table 1 ) who underwent de novo radiofrequency ablation to elimi-
were investigated. Serum Gal-3, CRP, and BNP were measured in blood samples from the LA cavity and CS prior to ablation ( Figure 1A ). Gal-3 levels were greater in patients with persistent than paroxysmal AF, but CRP and BNP levels were not significantly different.
Notably, mean AF cycle length in V 1 was inversely related to Gal-3 serum levels in both LA and CS ( Figure 1B) , and LA volume index correlated positively with Gal-3 serum levels in both LA and CS ( Figure 1C ). Table 2 ). Receiveroperating characteristic curve analysis demonstrated that a Gal-3 level >13.05 ng/ml in CS and >11.9 ng/ml in LA ( Figure 1D ) was predictive of recurrences after a single ablation with 76% sensitivity and 71% specificity, and 81% sensitivity and 65% specificity, Body weight gain was comparable between GMCT and saline-treated groups. No animals developed heart failure (Supplemental Table 3 ). The AFassociated LA dilation was significantly attenuated in GMCT-treated compared to saline-treated animals ( Figure 3A) , which matched directly measured atrial
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protein in LA and PLA ( Figure 6D) . Therefore, the attenuation of APD shortening by GMCT during AF can be partially attributed to mitigation of I K1 increase, which is otherwise responsible for DF accel- (B) Representative dominant frequency (DF) maps during AF optical mapping in saline-treated (top) and GMCT-treated hearts (bottom).
(C) maximal DF, (D) number of rotations, (E) density of singularity points (SP), and (F) SP trajectory area in optical mapping for saline-treated (N ¼ 6) and GMCT-treated hearts (N ¼ 6). *p < 0.05, **p < 0.01. Abbreviations as in Figure 4 .
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We generated computational action potentials for persistent AF using a human atrial action potential model (Supplemental Figure 9) Gal-1 increases cardiac myofibroblast proliferation ( Figure 2D) , consistent with known properties
Upstream Anti-Gal-3 in Transition to Persistent AF of Gal-1 inducing dermal-and gingival-derived myofibroblast activation, migration, and proliferation (32) . However, GMCT did not inhibit the effect of Gal-1 at the same dose which completely inhibited Gal-3 proliferation, suggesting that GMCT has higher affinity and more specificity to Gal-3 than Gal-1. Moreover, Gal-1 protein in AF sheep tissue is reduced compared to sham ( Figure 4B ),
suggesting that Gal-1 may not be a key regulator of AF. Altogether, these data suggest that the beneficial effects of GMCT are due to Gal-3 inhibition and not Gal-1. Mann-Whitney U test. *p < 0.05, **p < 0.01. Abbreviations as in Figure 4 .
GMCT did not rescue AF-remodeled SERCA, NCX, or
RyR2.
In addition to decreasing AF inducibility, GMCT significantly increased the probability of spontaneous cardioversion to sinus rhythm during persistent AF, which may be explained by a combination of effects:
first, GMCT ameliorated atrial dilation and fibrosis, both of which are believed to contribute to a substrate for reentry; and second, GMCT significantly mitigated Takemoto et al.
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